公开(公告)号：NO950374D0

公开(公告)日：1995-02-01

申请号：NO950374

申请日：1995-02-01

Applicant: SEPRACOR INC ,  UNIV GEORGETOWN

Inventor： YOUNG JAMES W ,  GRAY NANCY M ,  WOOSLEY RAYMOND L ,  CHEN YIWANG

IPC: A61K9/48 ,  C07D211/22 ,  A61K31/137 ,  A61K31/165 ,  A61K31/192 ,  A61K31/445 ,  A61K31/451 ,  A61K31/60 ,  A61K45/00 ,  A61K45/06 ,  A61P17/00 ,  A61P27/16 ,  A61P37/08 ,  A61P43/00 ,  A61K

Abstract: Use of a composition comprising a compound of formula I: or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in providing symptomatic relief from dermal irritation, wherein the induction of cardiac arrhythmia is avoided, said treatment comprising administering a therapeutically effective amount of a compound of formula I to a human patient whose hepatic function is not impaired.

公开(公告)号：AU5549494A

公开(公告)日：1994-05-24

申请号：AU5549494

申请日：1993-11-02

Applicant: SEPRACOR INC

Inventor： GRAY NANCY M

IPC: C07D405/12 ,  A61K31/505 ,  A61P9/10

Abstract: Methods are disclosed utilizing the optically pure (+) isomer of doxazosin. This compound is a potent drug for the treatment of hypertension while avoiding the concomitant liability of adverse effects associated with the racemic mixture of doxazosin.

公开(公告)号：AU5457694A

公开(公告)日：1994-05-24

申请号：AU5457694

申请日：1993-11-02

Applicant: SEPRACOR INC

Inventor： GRAY NANCY M

IPC: A61K31/495

公开(公告)号：CA2147866A1

公开(公告)日：1994-05-11

申请号：CA2147866

申请日：1993-11-02

Applicant: SEPRACOR INC

Inventor： GRAY NANCY M

IPC: C07D405/12 ,  A61K9/20 ,  A61K9/48 ,  A61K31/496 ,  A61K31/505 ,  A61K31/517 ,  A61P9/10 ,  A61P13/08 ,  A61P35/00 ,  C07D237/10

Abstract: Methods and compositions are disclosed utilizing the optically pure (+) isomer of doxazosin. This compound is a potent drug for the treatment of benign prostatic hyperplasia while avoiding the concomitant liability of hypotensive effects associated with the racemic mixture of doxazosin. The optically pure (+) isomer of doxazosin is also useful for the treatment and prevention of atherosclerosis and other conditions related to elevated serum LDL and cholesterol levels, such as coronary artery disease, without the concomitant liability of adverse effects associated with the racemic mixture of doxazosin.

公开(公告)号：CA2139636A1

公开(公告)日：1994-01-20

申请号：CA2139636

申请日：1993-07-06

Applicant: SEPRACOR INC

Inventor： GRAY NANCY M ,  YOUNG JAMES W

IPC: C07D211/62 ,  A61K31/445 ,  A61K31/4468 ,  A61P1/00 ,  A61P1/08 ,  A61P1/10 ,  A61P1/14

Abstract: Methods are disclosed utilizing the optically pure (+) isomer of cisapride. This compound is a potent drug for the treatment of gastro-esophageal reflux disease while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cisapride. This compound is also useful in treating or preventing emesis while avoiding the adverse effects associate with racemic cisapride. The optically pure (+) isomer of cisapride is also useful for the treatment of dyspepsia and such other conditions as may be related to the activity of (+) cisapride as a prokinetic agent such as gastroparesis, constipation, post-opera-tive ileus, and intestinal pseudo-obstruction without the concomitant liability of adverse effects associated with the racemic mixture of cisapride. The (+) isomer of cisapride has been found to exhibit higher bioavailability over the racemic cisapride.

公开(公告)号：AU2005222506B2

公开(公告)日：2008-12-11

申请号：AU2005222506

申请日：2005-10-11

Applicant: SEPRACOR INC

Inventor： WONG JAMES W ,  CHEN YIWANG ,  GRAY NANCY M ,  WOOSLEY RAYMOND L

IPC: A61K31/445

公开(公告)号：DE69334145D1

公开(公告)日：2007-07-12

申请号：DE69334145

申请日：1993-08-03

Applicant: SEPRACOR INC

Inventor： YOUNG JAMES W ,  GRAY NANCY M ,  WOOSLEY RAYMOND L ,  CHEN YIWANG

IPC: A61K31/445 ,  A61K9/48 ,  C07D211/22 ,  A61K31/137 ,  A61K31/165 ,  A61K31/192 ,  A61K31/451 ,  A61K31/60 ,  A61K45/00 ,  A61K45/06 ,  A61P17/00 ,  A61P27/16 ,  A61P37/08 ,  A61P43/00

Abstract: Use of a composition comprising a compound of formula I: or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in providing symptomatic relief from dermal irritation, wherein the induction of cardiac arrhythmia is avoided, said treatment comprising administering a therapeutically effective amount of a compound of formula I to a human patient whose hepatic function is not impaired.

公开(公告)号：AU782660B2

公开(公告)日：2005-08-18

申请号：AU9740901

申请日：2001-12-24

Applicant: SEPRACOR INC

Inventor： YOUNG JAMES W ,  GRAY NANCY M ,  WOOSLEY RAYMOND L ,  CHEN YIWANG

IPC: A61K31/445

公开(公告)号：DE10199031I1

公开(公告)日：2001-10-04

申请号：DE10199031

申请日：1993-09-22

Applicant: SEPRACOR INC

Inventor： GRAY NANCY M

IPC: C07D241/04 ,  A61K31/495 ,  A61P11/00 ,  A61P37/08

公开(公告)号：CA2141572C

公开(公告)日：2001-02-06

申请号：CA2141572

申请日：1993-08-03

Applicant: UNIV GEORGETOWN ,  SEPRACOR INC

Inventor： YOUNG JAMES W ,  GRAY NANCY M ,  WOOSLEY RAYMOND L ,  CHEN YIWANG

IPC: C07D211/22 ,  A61K9/48 ,  A61K31/137 ,  A61K31/165 ,  A61K31/192 ,  A61K31/445 ,  A61K31/451 ,  A61K31/60 ,  A61K45/00 ,  A61K45/06 ,  A61P17/00 ,  A61P27/16 ,  A61P37/08 ,  A61P43/00

Abstract: A pharmaceutical composition comprising a compound of formula (I): wherein Z is COOH, COOCH3 or CH2OH, or a pharmaceutically acceptable salt thereof, for use in an anti-histaminic treatment which does not induce any significant cardiac arrhythmia, comprising administering a therapeutically effective amount of a compound of formula (I) to a human patient.